Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.43 USD
Change Today -0.2099 / -2.75%
Volume 230.0
ARDM On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

aradigm corp (ARDM) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $11.41
52 Week Low
03/27/15 - $6.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARADIGM CORP (ARDM)

Related News

No related news articles were found.

aradigm corp (ARDM) Related Businessweek News

No Related Businessweek News Found

aradigm corp (ARDM) Details

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). The company is conducting Phase 3 clinical trials with Pulmaquin in BE; Phase 2b trial with Lipoquin and Pulmaquin in BE. It has also completed a Phase 2a trial with Lipoquin in CF and Phase 2a trial with Lipoquin in BE. The company’s proprietary program under development comprises ARD-1600 Inhaled Nicotine, a smoking cessation therapy. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

18 Employees
Last Reported Date: 03/18/15
Founded in 1991

aradigm corp (ARDM) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $400.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $305.0K
Chief Medical Officer
Total Annual Compensation: $365.0K
Compensation as of Fiscal Year 2014.

aradigm corp (ARDM) Key Developments

Aradigm Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Aradigm Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $8,768,000 compared with $6,631,000 a year ago. Loss from operations was $1,139,000 against $822,000 year ago. Net loss and comprehensive loss was $1,163,000 or $0.08 per basic and diluted share against net income of $7,755,000 or $0.53 per basic and diluted share a year ago. The increase in revenue was due to the recognition of revenue from the Grifols collaboration arrangement as the company is being reimbursed for Pulmaquin investigational inhaled ciprofloxacin project-related costs, as well as the revenue recognized from work being conducted under NIH grants.

Aradigm Corporation Appoints Robert A. Reed as Vice President, Regulatory (Cmc) and Quality

Aradigm Corporation announced that Robert A. Reed, PhD has been appointed as Aradigm’s Vice President, Regulatory (CMC) and Quality, reporting to Igor Gonda, President and Chief Executive Officer. Dr. Reed joins Aradigm from Celsion Corporation where he was Senior Vice President of CMC and Technical Operations, overseeing CMC Regulatory and Operations for a liposomal delivery system under clinical development for the treatment of primary liver cancer. Dr. Reed has more than 25 years of pharmaceutical industry experience in preclinical, CMC and regulatory activities spanning The Liposome Company, Merck & Company, XenoPort Incorporated and Celsion Corporation. While at Merck & Co., Dr. Reed directed the CMC activities of many late stage products, such as Crixivan®, Singulair® and Januvia®.

Aradigm Corporation - Shareholder/Analyst Call

To provide a corporate overview, including an update on the development program for the investigational drug Pulmaquin - the company's proprietary inhaled antibiotic product candidate currently in two Phase 3 clinical trials in non-CF BE patients


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARDM:US $7.43 USD -0.2099

ARDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexza Pharmaceuticals Inc $1.06 USD -0.0316
Alkermes PLC $67.53 USD -0.86
Bayer AG €133.88 EUR -1.75
Gilead Sciences Inc $117.90 USD +2.19
GlaxoSmithKline PLC 1,389 GBp +14.50
View Industry Companies

Industry Analysis


Industry Average

Valuation ARDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARADIGM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at